Delays at the Food and Drug Administration have left Dornier withouta production line shock-wave lithotripter approved for sale inthe U.S. Dornier Medizintechnik of Munich has discontinued productionof its HM-4 lithotripter, while the FDA has not yet
Delays at the Food and Drug Administration have left Dornier withouta production line shock-wave lithotripter approved for sale inthe U.S. Dornier Medizintechnik of Munich has discontinued productionof its HM-4 lithotripter, while the FDA has not yet approved itssuccessor, the MFL 5000.
"The problem with being a worldwide manufacturer is youcannot run your production line solely for the U.S.," saidRobert Minton, vice president of marketing for Dornier MedicalSystems of Marietta, GA. "You have to take into considerationthe product needs of all markets."
"Adequate numbers" of HM-4s to meet forecasted needsin the U.S. have been manufactured, Minton said.
While there are HM-4s in warehouses, many, if not all, of thesesystems have been contracted for. "It is important to usthat the FDA look favorably on our new product," said RichardCline, vice president of service.
Dornier is struggling to maintain dominance of a U.S. marketit created in December 1984. Total sales of extracorporeal shock-wavelithotripsy (ESWL) units reached about 71 units in 1987 and thenplummeted, according to Market Intelligence Research of MountainView, CA. Industry sources agree that total sales in 1990 wereless than 30 units. The sluggish market is expected to continuethis year.
Siemens is challenging Dornier for leadership in this shrunkenmarket and may be succeeding.
Seventy-five percent of U.S. units installed in 1989 were SiemensLithostars, according to Laura Lee Murphy, Siemens sales managerfor lithotripsy and urology systems. Siemens' final 1990 figuresare not available.
Dornier will not comment on market share for the past two years.It has about 80% of the installed base and hopes to retain theleadership role in orders and installations, according to Minton.
Dornier officials are working with the FDA to answer specificquestions regarding its submission for the MFL 5000. The companyexpects to be back in the game soon with a production line lithotripter.
"The results of our IDE (investigational device exemption)trials were actually better than for our HM-3s (the first ESWLmachines introduced to the U.S.)," Minton said. "Basedon that track record, we're confident that the machine will gothrough approval fairly easily."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 5th 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 5th 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Reducing the Interval Breast Cancer Rate of Screening DBT: Can AI Have an Impact?
August 5th 2025In a retrospective review of screening digital breast tomosynthesis (DBT) exams for over 200 women with interval breast cancers, researchers found that AI provided accurate localization of cancers in 32.6 percent of the cases.